Pharmaceutical

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.

Aug 31, 2024 - 04:00
ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam
Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.
Read the original article

Tags:

Previous Article

J&J targets generalised myasthenia gravis landscape with nipocalimab

Next Article

ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy

FDA grants accelerated approval for PTC’s AADC deficien...

Nov 15, 2024

STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal

STAT+: Pharmalittle: Pfizer halts development of twice-...

Dec 1, 2023

Olanzapine by Neurelis for Bipolar Disorder (Manic Depr...

Jun 18, 2024